[Clinical experience with CS-1170 (author's transl)].

Area of Science:

• Pediatric Infectious Diseases
• Pharmacology
• Bacteriology

Background:

• Acute purulent osteomyelitis is a serious pediatric infection requiring effective antimicrobial treatment.
• The development of novel antimicrobial agents is crucial for combating resistant bacterial strains.
• CS-1170 is an investigational drug evaluated for its efficacy in pediatric infections.

Observation:

• CS-1170 was administered to six pediatric patients with various infections.
• Detailed case studies focused on patients with acute purulent osteomyelitis.
• Clinical responses were categorized as excellent, fair, poor, or unknown.

Findings:

• Excellent clinical response was observed in 3 out of 6 patients.
• CS-1170 successfully cured cases of acute purulent osteomyelitis.
• One patient showed a fair response, one a poor response, and one outcome was unknown.

Implications:

• CS-1170 shows promise as an effective treatment for pediatric bacterial infections, including osteomyelitis.
• Further investigation is warranted to optimize CS-1170 dosage and patient selection.
• The findings support the potential of CS-1170 in pediatric clinical practice.